Semaglutide Weight Loss Approval: Evidence & Biomarkers

Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide received FDA approval for chronic weight management in November 2021 under the brand name Wegovy. The approval was based on STEP clinical trials demonstrating approximately 15% average body weight loss over 68 weeks in patients with obesity or overweight status with weight-related comorbidities.

Beyond awareness of FDA approval status, understanding your individual metabolic and genetic profile can help guide a conversation with your healthcare provider about whether semaglutide aligns with your specific health situation. PlexusDx supports precision-wellness decision-making by connecting clinical evidence to personalized biomarker and genetic context.

FDA Approval Timeline and Indication for Semaglutide

The FDA approved semaglutide (Wegovy) for chronic weight management on November 4, 2021. The indication applies to adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease. Approval followed successful Phase 3 STEP trials.

Semaglutide is distinct from its diabetes formulation (Ozempic). Wegovy uses subcutaneous injection at doses up to 2.4 mg weekly, titrated over 16 weeks. Insurance coverage varies widely; many plans require documented comorbidities and failed lifestyle interventions before approval. Provider prescription and ongoing monitoring are essential.

Clinical Efficacy Data: What the STEP Trials Revealed

The four STEP trials enrolled over 4,500 patients and evaluated semaglutide's weight loss efficacy. Results consistently demonstrated superior outcomes versus placebo across diverse populations, including those with and without type 2 diabetes. Real-world outcomes depend heavily on adherence, lifestyle factors, and individual metabolic response.

Trial Parameter	Semaglutide Group	Placebo Group
Average Weight Loss	15% body weight (range 10–17%)	2–3% body weight
Responder Rate	86% lost ≥5% body weight	31% lost ≥5% body weight
Cardiovascular Events	Reduced by 26%	Baseline rate
Time to Goal	16–68 weeks depending on dose	Not achieved in placebo

Mechanism of Action: How Semaglutide Promotes Weight Loss

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone regulating appetite and blood glucose. It acts on receptors in the hypothalamus and brainstem to increase satiety, reduce hunger signals, and slow gastric emptying. These mechanisms lower caloric intake and support sustained weight loss when combined with behavioral changes.

Individual response to GLP-1 agonists varies significantly based on differences in GLP-1 receptor expression, baseline metabolism, and genetic factors. Some patients experience robust appetite suppression and sustained weight loss, while others achieve modest benefits. Provider monitoring and dose adjustment are standard practice to optimize outcomes and manage side effects.

Eligibility, Safety Considerations, and Who Should Consult a Provider

Semaglutide is not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pregnancy, and severe renal or hepatic impairment. Patients with diabetic retinopathy should use caution. A comprehensive medical evaluation by a healthcare provider is mandatory before initiation.

Common side effects include nausea, vomiting, constipation, and diarrhea, typically mild and transient. Rare but serious risks include pancreatitis, gallbladder disease, and acute kidney injury. Ongoing provider supervision ensures early detection of adverse effects and supports dose titration decisions. Weight regain often occurs after discontinuation, necessitating long-term engagement with lifestyle and treatment strategies.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in key GLP-1 pathway genes, including GLP1R rs6923761 and GIPR rs1800437, which may help provide context about your individual genetic predisposition to GLP-1 receptor sensitivity. These insights can support a more informed conversation with your provider about whether semaglutide or alternative GLP-1 agents align with your metabolic profile.

The genetic test reveals predispositions in peptide metabolism pathways, not exact medication response or approval status. A variant associated with higher GLP-1 receptor expression, for example, may correlate with greater appetite-suppression response in some populations, but individual outcomes remain variable. These findings should be interpreted with a qualified healthcare provider as one factor among clinical history, comorbidities, and lifestyle readiness.

Understanding your genetic and metabolic context empowers a deeper conversation with your provider about which treatment option—whether semaglutide, compounded alternatives, or other approaches—may offer the best fit for your weight management goals. PlexusDx compounded semaglutide options provide access at various dosing and delivery points while your provider guides personalized titration and monitoring.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.